Kornimate/medical-research-clean huggingface dataset:
effects of goat milk yogurt on postprandial glycemic responses, arterial blood pressure and energy intake

Conditions: Potential Abnormality of Glucose Tolerance; Appetite; Lack or Loss, Nonorganic Origin

Summary: this study investigated any potential associations between two preloads offered as snacks and postprandial glycemic response, subjective appetite and energy intake in healthy, normal weight adults

this study aimed at 1. firstly determine the glycemic index (gi) of a) goat milk yogurt b) goat milk yogurt with currants, c) currants and d) sultanina raisins, all containing 25 gr available carbohydrates and 2. test the hypothesis that a goat milk yogurt consumed as a snack before a meal, compared to milk with lactic acid would: a) have greater short-term effect on satiety measured by subsequent ad libitum meal intake, b) induce greater satiety as assessed by visual analogue scales (vas) and c) reduce postprandial glycemic response.

Eligibility criteria:
inclusion criteria: * healthy, non-smoking, non-diabetic men and women individuals with normal body mass index (bmi; between 18.5 and 24.9 kg/m2) exclusion criteria: * severe chronic disease (e.g. tumors, manifest coronary heart disease, diabetes mellitus, severe kidney or liver conditions, endocrine and immunological conditions) * gastrointestinal disorders (e.g. chronic inflammatory bowel disease) * lactose intolerance * pregnancy * competitive sports * lactation * alcohol * drug dependency
the value of tranxemic acid to reduce intraoperative blood loss during elective cesarean sections in high risk women

Conditions: Intraoperative Bleeding

Summary: a full medical history will be obtained from all participants. obstetric ultrasonography and laboratory tests will be performed.according to group assignment, either 1 g(10 ml) tranexamic acid stored in a dry container at 15 °c-30 °c) diluted in 20 ml of 5% glucose or 30 ml of 5% glucose will be slowly administered intravenously 15 minutes before skin incision over a 5-minute period. following delivery, patients in both groups will receive an intravenous bolus of 5 iu oxytocin , 1 ml(0.2 mg) intramuscular ergometrine , and 20 iu oxytocin in 500 ml lactated ringer's solution(infused at a rate of 125 ml/h)

a full medical history will be obtained from all participants. obstetric ultrasonography and laboratory tests will be performed, including prothrombin time, prothrombin concentration, complete blood count, and liver and kidney function tests. maternal body weight and vital signs (heart rate, blood pressure, and respiratory rate) will be checked 30 minutes before surgery. according to group assignment, either 1 g(10 ml) tranexamic acid (kapron, amoun, egypt; stored in a dry container at 15 °c-30 °c) diluted in 20 ml of 5% glucose or 30 ml of 5% glucose will be slowly administered intravenously 15 minutes before skin incision over a 5-minute period. following delivery, patients in both groups will receive an intravenous bolus of 5 iu oxytocin (syntocinon, novartis, basel, switzerland), 1 ml(0.2 mg) intramuscular ergometrine (methergin, novartis, basel, switzerland), and 20 iu oxytocin in 500 ml lactated ringer's solution(infused at a rate of 125 ml/h). fluid monitoring will be performed through rate of infusion and urine output. a complete blood count test will be performed 24 hours after delivery. on discharge, patients who received tranexamic acid will be given a brief orientation regarding symptoms and signs of a thromboembolic event and will be instructed to contact the investigators immediately if any occurred. all patients will be examined for thromboembolic events at the 1- and 4-week follow-up visits ebl will be calculated according to the formula: ebl = ebv x preoperative hematocrit-postoperative hematocrit preoperative hematocrit where ebv is estimated blood volume (ml; weight in kg × 85). for a two-tailed test at an α level of 0.05, the difference between the two groups regarding the primary outcome measure (ebl) had a power of 1.0 (100%) in a post hoc calculation.

Eligibility criteria:
inclusion criteria: * • grand multipara * multiple pregnancy * polyhydraminos (afi is more than 24 cm). * placenta previa * gestational diabetes mellitus * preeclampsia * anemia complicating pregnancy (hemoglobin is less than 11 gm/dl) exclusion criteria: * • allergy to tranxemic acid. * h/o suggestive of bleeding disorders * previous history of deep vein thrombosis * abnormally invasive placenta * emergency cesarean sections * intraoprative complications during cesarean sections as uterine artery injury and broad ligamentary hematoma.
investigation of burnout, musculoskeletal system and aerobic capacity in nurses

Conditions: Aerobic Capacity

Summary: the aim of our study was to evaluate the relationship of aerobic capacity with burnout status, musculoskeletal system, physical performance and exercise benefit/obstacle perception in nurses, who have an important place in the health profession group, and to bring the results to the literature. demographic information will be obtained from the participants who volunteered to participate in the study. burnout, musculoskeletal pain and physical performance will be evaluated with relevant scales and aerobic capacity will be measured with a bicycle ergometer.

in the literature, there are studies on the general effects of aerobic exercises on the cardiovascular system, musculoskeletal system, endocrine system, nervous system and psychosocial status. however, despite the benefits of aerobic exercises and the physiological and psychological importance of high aerobic capacity, there are no studies in the literature that examine the factors associated with the aerobic capacity of nurses. these factors affect the professional life of nursesthe aim of our study was to evaluate the relationship of aerobic capacity with burnout status, musculoskeletal system, physical performance and exercise benefit/obstacle perception in nurses, who have an important place in the health profession group, and to bring the results to the literature. demographic information will be obtained from the participants who volunteered to participate in the study. burnout, musculoskeletal pain and physical performance will be evaluated with relevant scales and aerobic capacity will be measured with a bicycle ergometer.

Eligibility criteria:
inclusion criteria: * 18-65 years old * at least 1 year of experience * nurses not working in the academic field exclusion criteria: * pregnancy * malignancy * nurses with lower extremity problems

Keywords: nurse aerobic capacity burnout
study of the metrological properties of two assessment grids of the driving capacity after a cerebrovascular accident (roadtrip)

Conditions: Stroke

Summary: precise recommendations concerning the methods of evaluation for the resumption of the driving after a not evolutionary stroke were recommended recently by the high authority of health. these describe among others elements to be estimated during the test on the road, in the presence of the driving instructor who remains gold standard. however, no standardized assessment grid serving as decision-making tool is at present validated. actually the test made by the unit of evaluation of the automobile resumption of the university hospital on the road, in a car of apprenticeship with double pedals and in the presence of a professional binomial (driving instructor and occupational therapist) then validated by the opinion of the doctor of the service. the current standard is thus very subjective and lack of sensibility. it is necessary to study the metrological properties of both available assessment grids (that established from the recommendations of the has and trip), none of them reached a level of validation enough in this population. the trip is this day validated only at the elderly people. the hypothesis of the search is an insufficiency of trip to estimate the patients presenting aftereffects of cerebrovascular accident. the main objective of this work is to validate the new assessment grid after a study of its metrological properties in the situation of the driving on the road.

the patients will benefit a medical consultation to estimate the possibility of inclusion in the study. during this consultation, the results of the neuropsychological and ophthalmological examinations will be explored and a specificity of the sensitive-driving deficits presented by the patient will be estimated to recommend the arrangements of necessary vehicle if necessary. all the inclusive patients will benefit then the first test of driving in "ecological" situation accompanied by a lasting driving instructor during 45minutes. the evaluation will be realized by a present occupational therapist and a neuropsychologist in the vehicle, on two different assessment grids. the second test on road will be for the part of included patients and will be made with the driving instructor and the therapist. then, the third test on road will be realized after sessions on driving simulator for the part of the patients requiring a re-entrainment.

Eligibility criteria:
inclusion criteria: * 18 years to 80 years * cognitive and/or sensitive-motor disorders after a cerebrovascular accident * candidate for resumption of driving on the road and having to pass an aptitude test * french legal protection exclusion criteria: * contraindications for resumption of driving on the road (visual field amputation, binocular visual acuity less than 5/10; cognitive impairment not compatible with driving; other medical contraindication). * protected populations not concerned by the study (guardianship, curatorship, deprived of the freedoms, safeguarding of justice).

Keywords: driving capacity cerebrovascular accident grid
the effects of continuous transversus abdominis plane (tap) catheters on postoperative pain after renal transplantation

Conditions: Pain

Summary: up to 174 patients undergoing renal transplantation will be randomized to one of two groups. randomization will be based on computer-generated codes using random block sizes ranging from 4 to 8. group 1: tap catheter with continuous infusion of ropivicaine group 2: fentanyl iv pca the tap catheter will be removed 48 hours postoperatively. following removal, the pain scores will be assessed at 60 and 72 hours postoperatively to determine any prolonged analgesic benefit. in addition, the presence of any pain at the incision site will be noted at the 1 month surgical follow-up to determine any evidence of chronic pain. the investigators hypothesis is that unilateral kidney transplant patients with a continuous tap catheter will have decreased pain scores and opioid usage compared to those receiving standard analgesic therapy.


Eligibility criteria:
inclusion criteria: * the patient is \>18 years of age * the patient has provided written informed consent and understands the explanation of the protocol. * the patient is scheduled to have a unilateral renal transplant with a flank incision exclusion criteria: * patients aged \<18. * patients with a known allergy to amide local anesthetics or para-aminobenzoic acid. * patients who are unable to understand the verbal analog pain scale. * patients who decline participation. * patients with a midline abdominal incision. * combined transplants, ie. kidney-pancreas

Keywords: renal transplant flank incision
real-time near-infrared (nir) mapping of sentinel lymph nodes in breast cancer

Conditions: Breast Cancer

Summary: the objective of this phase ii study is to assess the diagnostic accuracy of sentinel lymph node (sln) identification in patients with breast cancer using near-infrared (nir) fluorescence optical imaging.

fifty participants consented from brigham and women's hospital (currently enrolling) and beth israel deaconess medical center (currently non-enrolling), who will be undergoing standard of care for breast cancer sln mapping with tc-99m will be enrolled in this study. prior to surgery, patients will undergo lymphoscintigraphy as is standard of care. at the time of sln mapping, the patient will be injected with indocyanine green dye (icg). concurrently, a custom-designed imaging platform that utilizes nir fluorescence optics will be employed to identify the dye and its path through the lymphatic track, and its eventual highlighting of the sln. both color images and nir images will be merged to give the operating surgeon a clear picture of the icg track superimposed over anatomical landmarks. this technique will identify the sln and provide an accurate video image of its location. the surgeon will resect all slns identified by tc-99m or nir fluorescence, and then confirm the radioactivity and nir fluorescence signal in each after resection.

Eligibility criteria:
inclusion criteria: * participant must have histologically confirmed breast cancer and be deemed an appropriate surgical candidate with consent for a sentinel lymph node mapping by their oncologic surgeon. * age minimum: 18 years. * participant must be receiving a planned lymphoscintigraphy procedure. * participant must have the ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * participants who choose not to proceed with sentinel lymph node biopsy. * history of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy. * women who are pregnant or may become pregnant, as well as those women who are breastfeeding, will be excluded from this study.

Keywords: breast cancer sentinel lymph node mapping intraoperative imaging
immediate effect of irradiation with low-level laser therapy on the electromyographic activity of the upper trapezius muscles and the level of pain among patients with non-specific neck pain

Conditions: Neck Pain Treatment

Summary: the aim of the present study is to assess the immediate effect of irradiation with low level laser therapy (lllt) on the electromyographic activity of upper trapezius muscles and the amount of pain felt by patients with non-specific neck pain (ns-np).a total of 20 patients with non-specific neck pain will be enrolled in a randomized, single-blind, crossover study. each subject will receive two forms of treatment in random order: a single session of lllt and placebo lllt. in order to eliminate carry-over treatment effects, a one-week wash-out period will be respected between sessions. surface electromyography will be used to determine nerve conduction velocity and activity in the upper trapezius muscles before and after treatment. the outcome measures will be determined by a numerical pain rating scale. comparisons before and after irradiation with lllt will determine the activity of the upper trapezius muscles and the level of pain. the data will be submitted to statistical tests considering a p-value of p \< 0.05.


Eligibility criteria:
inclusion criteria: * 18 to 40 years * male and female volunteers * history of neck pain for a period of more than two months * score ranging from 15 to 24 on the neck disability index * score ranging from three to seven points on an 11-point (range: 0 to 10) numerical rating scale (nrs) for perceived pain intensity exclusion criteria: * history of neurological disorders * neck surgery * chronic neck pain resulting from a traumatic incident * chronic musculoskeletal condition * medical diagnosis of fibromyalgia; systemic disease * connective tissue disorder * having undergone physical therapy use of analgesic, muscle relaxant.

Keywords: low-level laser therapy trapezius muscle neck pain
ultrasound effect with hyaluronate injection on risk of fall in geriatric women with knee osteoarthritis

Conditions: Osteo Arthritis Knee

Summary: for many years' physiotherapists have been using ultrasound in treatment of knee osteoarthritis especially in geriatrics (people aged above 65 years) for its known therapeutic effect in relieving pain and improving knee function. hyaluronan is used to treat osteoarthritis of the knee. such treatments, called viscosupplementation, are administered as a course of injections into the knee joint, and are believed to supplement the viscosity of the joint fluid, thereby lubricating the joint, cushioning the joint, and producing an analgesic effect. studies reveals the risk for falls increases with additional symptomatic oa lower limb joints and confirms in addition to gender factor; including female sex.

it is hypothesized that physical therapy by ultrasound might add some extra benefit on risk of fall when applied after intra-articular hyaluronate of knee oa in female geriatrics. so, forty female geriatrics with ages ranged from 65 to 75 years, randomly will be selected from ahmed maher teaching hospital, kasr el einy hospital, charity clinic and outpatient clinic of badr university, referred to physical therapy by an orthopedic surgeon. all will be diagnosed as chronic oa of one or both knees where conventional therapeutic measures failed. they will be assigned to begin ha intra-articular knee injection by the orthopedic surgeon once weekly for 3 weeks. these patients will be randomly divided into 2 groups equal in number, group (1) the study group, they will receive ha intra-articular injection in addition to 12 sessions of therapeutic ultrasound, while group (2) served as the control group receiving only ha intra-articular knee injection.

Eligibility criteria:
inclusion criteria: * patients' ages above 65 years. * patients diagnosed as chronic osteoarthritis of more than 5 years. * the oa diagnosed as grade (iii to v) * patients failed with conventional treatment. * all patients followed up with the same orthopedic surgeon, and they took the same type of ha intra-articular injection (ha of high mw 3000 kda). * all patients were medically stable and do not suffer from any other diseases which may affect the trial results. * all patients were not treated with analgesics or any medication which may cause misleading results. * none of the patients received intra-articular hyaluronic acid injection for 1 year or intra-articular corticosteroid injection within the last 3 months. * all patients didn't take or oral glucosamine or chondroitin supplements or stopped these drugs 2-3 months before participating in this study. * every patient signed a consent form. exclusion criteria: * young individuals (their age is below 65 years old). * mild degree of oa (grade i \& ii). * patients who had undergone knee arthroscopy, or any knee surgery. * patients with oa secondary to trauma. * patients with metal implants. * patients with cns dysfunction.

Keywords: risk of fall osteoarthritis hyaluronate geriatric females
use of st250 to reconstruct lateral tongue defects

Conditions: Tongue Neoplasms

Summary: to assess the use of suprathel 250 for mucosal reconstruction in the head \& neck region. the membrane is applied to reconstruct lateral tongue defects . healing of the mucosa and regaining of normal tongue movement and speech are assessed postoperatively.

lateral tongue defects are usually treated using radial fore-arm free grafts which require a prolonged hospital stay with higher morbidity rates. it also entails the need of multiple rehabilitation and remodeling porcdures of the transplnted flap to enable intelligible speech and tongue function.

Eligibility criteria:
inclusion criteria: * lateral tunge defects (postoncologic resection) exclusion criteria: * radio / chemotherapy * pregnant/ breastfeeding women

Keywords: tongue defect reconstruction polylactide membrane
multicenter evaluation in patients with meningiomas of the response to treatment with 177lutetium-oxodotreotide

Conditions: Meningioma

Summary: meningiomas are the most common primary tumors of the central nervous system, representing more than a third of tumors.current conventional treatments for meningioma are surgery and radiotherapy. when these treatments are no longer feasible, meningiomas are considered refractory regardless of their grade. some meningiomas express somatostatin type 2 receptors and can be treated with lutathera. this study aims to evaluate the response to treatment in this pathology

in nuclear medicine, peptide receptor radionuclide therapy with 177lu-oxodotreotide, deploys an octreotide-like effect and appears very promising, with a preliminary progression free survival at 6 months of 94% and overall survival at 12 months of 88% in grade 1 meningiomas, and 28% with an overall survival at 12 months of 65% in grades 2 and 3 meningiomas. these results are nevertheless the result of a meta-analysis obtained from series of patients limited in number and heterogeneous in terms of type of treatment modality. at the request of healthcare professionals and in consultation with the advanced accelerator applications laboratory, the agency of the drug security has developed a compassionate prescribing framework aimed at securing the use of lutathera in meningiomas of all grades, expressing type 2 somatostatin in imaging of nuclear medicine, after failure of the standard treatment (surgery, radiotherapy/radio-surgery) or impossibility of carrying it out (multiple lesions, inaccessible lesions), at the suggestion of the national comitee omega (april 6, 2022). this cohort has the advantage of being consistent and homogeneous in terms of type of treatment and method of administration.

Eligibility criteria:
inclusion criteria: * patients who have benefited from treatment with lutathera® within the framework of compassionate prescription in a refractory meningioma of any grade * patient informed via an information and non-opposition to the use of their pseudonymized data for research purposes (research objectives clearly explained in the letters) exclusion criteria: -patient opposition to the use of their data for this research
a master protocol to evaluate the long-term safety of (ly3527727) pirtobrutinib

Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma

Summary: the master protocol study j2n-mc-jzny provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. the clinical studies that will feed into this master protocol are referred to as originator studies. the master protocol will govern individual study-specific appendices (isas) that will represent participants from the individual, completed originator studies. these participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. overall, the master protocol and the individual isas, when combined, define the investigations for this study.


Eligibility criteria:
inclusion criteria: * are participating in an eligible lilly sponsored clinical study evaluating pirtobrutinib. exclusion criteria: * are pregnant, or intend to become pregnant during the study, or within 30 days of last dose of study treatment or to breastfeed during the study or within 1 week of the last dose of study treatment.